Halozyme Therapeutics (HALO)
NASDAQ:HALO
Want to see HALO full AI Analyst Report?
Halozyme (HALO) Ownership Overview
1.07% Insiders
27.41% Mutual Funds
6.67% Other Institutional Investors
28.65% ETFs
36.19% Public Companies and Individual Investors
The ownership structure of Halozyme (HALO) stock is a mix of institutional, retail, and individual investors. Approximately 62.74% of the company’s stock is owned by Institutional Investors, 1.07% is owned by Insiders, and 36.19% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
Date | Name | Activity | Value |
|---|---|---|---|
Mar 10, 2026 | xxxxxxxxxxxxx | $1955137 |
Recent Hedge Fund Trading Activity
Date | Firm | Activity | Value |
|---|---|---|---|
Dec 31, 2023 | xxxxxxxxxxxxx | $287909 | |
Dec 31, 2023 | xxxxxxxxxxxxx | $37794132 | |
Dec 31, 2023 | xxxxxxxxxxxxx | $9499260 | |
Dec 31, 2023 | xxxxxxxxxxxxx | $3533250 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 12,912,107 | Institution | 10.90% | 825,858,364 | |
| 10,237,859 | Institution | 8.64% | 654,813,462 | |
| 9,133,567 | Institution | 7.71% | 584,182,945 | |
| 3,559,206 | Institution | 3.00% | 227,646,816 | |
| 3,205,964 | Institution | 2.71% | 205,053,457 | |
| 1,373,614 | Institution | 1.16% | 87,856,351 | |
| 1,366,502 | Institution | 1.15% | 87,401,468 | |
| 1,175,910 | Institution | 0.99% | 75,211,204 | |
| 1,175,300 | Institution | 0.99% | 75,172,188 | |
| 1,104,264 | Institution | 0.93% | 70,628,725 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 9,133,567 | Institution | 7.71% | 584,182,945 | |
| 3,205,964 | Institution | 2.71% | 205,053,457 | |
| 1,175,910 | Institution | 0.99% | 75,211,204 | |
| 1,175,300 | Institution | 0.99% | 75,172,188 | |
| 1,101,354 | Institution | 0.93% | 70,442,602 | |
| 1,094,930 | Institution | 0.92% | 70,031,723 | |
| 1,027,105 | Institution | 0.87% | 65,693,636 | |
| 857,921 | Institution | 0.72% | 54,872,627 | |
| 775,438 | Institution | 0.65% | 49,597,014 | |
| 760,014 | Institution | 0.64% | 48,610,495 |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 4,200,163 | Institution | 3.55% | 138,017,356 | |
| 3,972,250 | Institution | 3.35% | 254,065,110 | |
| 3,737,645 | Institution | 3.15% | 241,563,996 | |
| 2,724,480 | Institution | 2.30% | 176,083,142 | |
| 1,524,978 | Institution | 1.29% | 98,559,328 | |
| 1,420,745 | Institution | 1.20% | 90,444,627 | |
| 1,313,736 | Institution | 1.11% | 84,906,758 | |
| 1,109,417 | Institution | 0.94% | 70,958,311 | |
| 889,684 | Institution | 0.75% | 56,904,189 | |
| 863,547 | Institution | 0.73% | 55,232,466 |
FAQ
Who Owns Halozyme Therapeutics (HALO)?
According to the latest TipRanks data, approximately 6.67% of the company's stock is held by institutional investors, 1.07% is held by insiders, and 36.19% is held by retail investors.
What percentage of Halozyme Therapeutics (HALO) stock is held by institutional investors?
According to the latest TipRanks data, approximately 6.67% of Halozyme Therapeutics (HALO) stock is held by institutional investors.
What percentage of Halozyme Therapeutics (HALO) stock is held by retail investors?
According to the latest TipRanks data, approximately 36.19% of Halozyme Therapeutics (HALO) stock is held by retail investors.
Who owns the most shares of Halozyme Therapeutics (HALO)?
iShares owns the most shares of Halozyme Therapeutics (HALO).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.